Drawing for A2 BIOTHERAPEUTICS

USPTO serial 97796895

A2 BIOTHERAPEUTICS

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
KOLODNER, LOUIS FRANCIS
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with A2 BIOTHERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*

Plus Government fees of $150

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joi A. White

Joi A. White CARR & FERRELL LLP411 BOREL AVENUE, SUITE 603SAN MATEO, CA 94402United States

Goods and services

ClassDescriptionStatusFirst use
005Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 5, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 4, 2026EX5GSOU EXTENSION 5 GRANTED—
Aug 12, 2026EXT5SOU EXTENSION 5 FILED—
Aug 12, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 14, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 13, 2026EX4GSOU EXTENSION 4 GRANTED—
May 13, 2026EXT4SOU EXTENSION 4 FILED—
May 13, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 14, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 13, 2025EX3GSOU EXTENSION 3 GRANTED—
Nov 13, 2025EXT3SOU EXTENSION 3 FILED—
Nov 13, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 13, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 12, 2025EX2GSOU EXTENSION 2 GRANTED—
May 12, 2025EXT2SOU EXTENSION 2 FILED—
May 12, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 11, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 11, 2024EX1GSOU EXTENSION 1 GRANTED—
Nov 12, 2024EXT1SOU EXTENSION 1 FILED—
Nov 12, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 21, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 26, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 26, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 6, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 6, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 16, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 16, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 16, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 16, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 17, 2023GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 17, 2023GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 17, 2023CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 14, 2023DOCKASSIGNED TO EXAMINER—
Mar 6, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 18, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance